New hope for advanced cancers: YL202 drug trial launches
NCT ID NCT07202364
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 22 times
Summary
This study tests an experimental drug called YL202 in about 100 adults with advanced solid tumors, including lung, colorectal, and cervical cancers that have not responded to other treatments. The main goal is to see if YL202 can shrink tumors. Participants will receive the drug and be monitored for side effects and how long the benefit lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Provincial Tumor Hospital
RECRUITINGChangsha, Hunan, 410006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.